ENTX vs PATH · rev $181.0K vs P/E 19, rev $1.61B
Entera Bio Ltd (ENTX) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Entera Bio Ltd (ENTX) is a biotechnology company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported ENTX revenue for 2024-12-31 was $181.0K. Net income was -$9.5M. ENTX currently screens at market cap $58.2M.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
ENTX currently screens at market cap $58.2M. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the ENTX and PATH stock pages for the full models.
Not investment advice.